nodes	percent_of_prediction	percent_of_DWPC	metapath
Frovatriptan—Change of bowel habit—Varenicline—nicotine dependence	0.127	0.147	CcSEcCtD
Frovatriptan—Urine abnormality—Varenicline—nicotine dependence	0.0265	0.0305	CcSEcCtD
Frovatriptan—Urine analysis abnormal—Varenicline—nicotine dependence	0.0249	0.0288	CcSEcCtD
Frovatriptan—Toothache—Varenicline—nicotine dependence	0.0241	0.0278	CcSEcCtD
Frovatriptan—Electrocardiogram abnormal—Varenicline—nicotine dependence	0.0224	0.0258	CcSEcCtD
Frovatriptan—Disturbance in attention—Varenicline—nicotine dependence	0.0169	0.0195	CcSEcCtD
Frovatriptan—Chest discomfort—Varenicline—nicotine dependence	0.0166	0.0191	CcSEcCtD
Frovatriptan—Gastrooesophageal reflux disease—Varenicline—nicotine dependence	0.0162	0.0187	CcSEcCtD
Frovatriptan—Thinking abnormal—Varenicline—nicotine dependence	0.016	0.0185	CcSEcCtD
Frovatriptan—Nocturia—Varenicline—nicotine dependence	0.0158	0.0182	CcSEcCtD
Frovatriptan—Eructation—Varenicline—nicotine dependence	0.0144	0.0166	CcSEcCtD
Frovatriptan—Salivary hypersecretion—Varenicline—nicotine dependence	0.0142	0.0164	CcSEcCtD
Frovatriptan—Urine output increased—Varenicline—nicotine dependence	0.0132	0.0153	CcSEcCtD
Frovatriptan—Hypertonia—Varenicline—nicotine dependence	0.0128	0.0148	CcSEcCtD
Frovatriptan—Mental disability—Varenicline—nicotine dependence	0.0127	0.0147	CcSEcCtD
Frovatriptan—Euphoric mood—Varenicline—nicotine dependence	0.0126	0.0145	CcSEcCtD
Frovatriptan—Polyuria—Varenicline—nicotine dependence	0.0121	0.014	CcSEcCtD
Frovatriptan—Eye pain—Varenicline—nicotine dependence	0.0118	0.0136	CcSEcCtD
Frovatriptan—Hot flush—Varenicline—nicotine dependence	0.0114	0.0131	CcSEcCtD
Frovatriptan—Amnesia—Varenicline—nicotine dependence	0.0113	0.0131	CcSEcCtD
Frovatriptan—Menopausal symptoms—Varenicline—nicotine dependence	0.0113	0.013	CcSEcCtD
Frovatriptan—Thirst—Varenicline—nicotine dependence	0.0112	0.0129	CcSEcCtD
Frovatriptan—Hypoglycaemia—Varenicline—nicotine dependence	0.0109	0.0126	CcSEcCtD
Frovatriptan—Osteoarthritis—Varenicline—nicotine dependence	0.0106	0.0123	CcSEcCtD
Frovatriptan—Affect lability—Varenicline—nicotine dependence	0.0105	0.0121	CcSEcCtD
Frovatriptan—Migraine—Varenicline—nicotine dependence	0.0105	0.0121	CcSEcCtD
Frovatriptan—Mood swings—Varenicline—nicotine dependence	0.0101	0.0116	CcSEcCtD
Frovatriptan—Dysphagia—Varenicline—nicotine dependence	0.00919	0.0106	CcSEcCtD
Frovatriptan—Pollakiuria—Varenicline—nicotine dependence	0.00849	0.0098	CcSEcCtD
Frovatriptan—Depression—Varenicline—nicotine dependence	0.00817	0.00943	CcSEcCtD
Frovatriptan—Acute coronary syndrome—Varenicline—nicotine dependence	0.00808	0.00932	CcSEcCtD
Frovatriptan—Myocardial infarction—Varenicline—nicotine dependence	0.00803	0.00927	CcSEcCtD
Frovatriptan—Stomatitis—Varenicline—nicotine dependence	0.00799	0.00922	CcSEcCtD
Frovatriptan—Conjunctivitis—Varenicline—nicotine dependence	0.00796	0.00919	CcSEcCtD
Frovatriptan—Epistaxis—Varenicline—nicotine dependence	0.00773	0.00892	CcSEcCtD
Frovatriptan—Sinusitis—Varenicline—nicotine dependence	0.00769	0.00887	CcSEcCtD
Frovatriptan—Bradycardia—Varenicline—nicotine dependence	0.00749	0.00864	CcSEcCtD
Frovatriptan—Hypoaesthesia—Varenicline—nicotine dependence	0.00732	0.00845	CcSEcCtD
Frovatriptan—Urinary tract disorder—Varenicline—nicotine dependence	0.00726	0.00839	CcSEcCtD
Frovatriptan—Urethral disorder—Varenicline—nicotine dependence	0.00721	0.00832	CcSEcCtD
Frovatriptan—Visual impairment—Varenicline—nicotine dependence	0.00709	0.00818	CcSEcCtD
Frovatriptan—Tinnitus—Varenicline—nicotine dependence	0.00686	0.00792	CcSEcCtD
Frovatriptan—Chills—Varenicline—nicotine dependence	0.0066	0.00762	CcSEcCtD
Frovatriptan—Arrhythmia—Varenicline—nicotine dependence	0.00657	0.00759	CcSEcCtD
Frovatriptan—Mental disorder—Varenicline—nicotine dependence	0.00644	0.00744	CcSEcCtD
Frovatriptan—Malnutrition—Varenicline—nicotine dependence	0.0064	0.00739	CcSEcCtD
Frovatriptan—Flatulence—Varenicline—nicotine dependence	0.00631	0.00728	CcSEcCtD
Frovatriptan—Dysgeusia—Varenicline—nicotine dependence	0.00627	0.00724	CcSEcCtD
Frovatriptan—Back pain—Varenicline—nicotine dependence	0.00619	0.00715	CcSEcCtD
Frovatriptan—Muscle spasms—Varenicline—nicotine dependence	0.00616	0.00711	CcSEcCtD
Frovatriptan—Tremor—Varenicline—nicotine dependence	0.006	0.00693	CcSEcCtD
Frovatriptan—Ill-defined disorder—Varenicline—nicotine dependence	0.00594	0.00686	CcSEcCtD
Frovatriptan—Agitation—Varenicline—nicotine dependence	0.00588	0.00679	CcSEcCtD
Frovatriptan—Malaise—Varenicline—nicotine dependence	0.00577	0.00667	CcSEcCtD
Frovatriptan—Vertigo—Varenicline—nicotine dependence	0.00575	0.00664	CcSEcCtD
Frovatriptan—Syncope—Varenicline—nicotine dependence	0.00574	0.00663	CcSEcCtD
Frovatriptan—Palpitations—Varenicline—nicotine dependence	0.00566	0.00653	CcSEcCtD
Frovatriptan—Loss of consciousness—Varenicline—nicotine dependence	0.00563	0.0065	CcSEcCtD
Frovatriptan—Convulsion—Varenicline—nicotine dependence	0.00555	0.0064	CcSEcCtD
Frovatriptan—CYP1A2—Xenobiotics—CYP2A7—nicotine dependence	0.00546	0.0492	CbGpPWpGaD
Frovatriptan—Myalgia—Varenicline—nicotine dependence	0.00545	0.00629	CcSEcCtD
Frovatriptan—Chest pain—Varenicline—nicotine dependence	0.00545	0.00629	CcSEcCtD
Frovatriptan—Arthralgia—Varenicline—nicotine dependence	0.00545	0.00629	CcSEcCtD
Frovatriptan—Anxiety—Varenicline—nicotine dependence	0.00543	0.00627	CcSEcCtD
Frovatriptan—Discomfort—Varenicline—nicotine dependence	0.00539	0.00622	CcSEcCtD
Frovatriptan—HTR1D—Monoamine GPCRs—DRD2—nicotine dependence	0.00535	0.0482	CbGpPWpGaD
Frovatriptan—Dry mouth—Varenicline—nicotine dependence	0.00533	0.00615	CcSEcCtD
Frovatriptan—HTR1B—Monoamine GPCRs—DRD2—nicotine dependence	0.00524	0.0472	CbGpPWpGaD
Frovatriptan—Shock—Varenicline—nicotine dependence	0.00514	0.00594	CcSEcCtD
Frovatriptan—Tachycardia—Varenicline—nicotine dependence	0.0051	0.00589	CcSEcCtD
Frovatriptan—Hyperhidrosis—Varenicline—nicotine dependence	0.00505	0.00583	CcSEcCtD
Frovatriptan—Anorexia—Varenicline—nicotine dependence	0.00498	0.00575	CcSEcCtD
Frovatriptan—Musculoskeletal discomfort—Varenicline—nicotine dependence	0.00476	0.0055	CcSEcCtD
Frovatriptan—Insomnia—Varenicline—nicotine dependence	0.00473	0.00546	CcSEcCtD
Frovatriptan—Dyspnoea—Varenicline—nicotine dependence	0.00466	0.00538	CcSEcCtD
Frovatriptan—Somnolence—Varenicline—nicotine dependence	0.00464	0.00536	CcSEcCtD
Frovatriptan—Dyspepsia—Varenicline—nicotine dependence	0.0046	0.00531	CcSEcCtD
Frovatriptan—Decreased appetite—Varenicline—nicotine dependence	0.00454	0.00524	CcSEcCtD
Frovatriptan—Fatigue—Varenicline—nicotine dependence	0.0045	0.0052	CcSEcCtD
Frovatriptan—HTR1D—Amine ligand-binding receptors—DRD2—nicotine dependence	0.0045	0.0405	CbGpPWpGaD
Frovatriptan—Constipation—Varenicline—nicotine dependence	0.00447	0.00516	CcSEcCtD
Frovatriptan—Pain—Varenicline—nicotine dependence	0.00447	0.00516	CcSEcCtD
Frovatriptan—HTR1B—Amine ligand-binding receptors—DRD2—nicotine dependence	0.0044	0.0397	CbGpPWpGaD
Frovatriptan—Feeling abnormal—Varenicline—nicotine dependence	0.00431	0.00497	CcSEcCtD
Frovatriptan—Gastrointestinal pain—Varenicline—nicotine dependence	0.00427	0.00493	CcSEcCtD
Frovatriptan—Abdominal pain—Varenicline—nicotine dependence	0.00413	0.00477	CcSEcCtD
Frovatriptan—Body temperature increased—Varenicline—nicotine dependence	0.00413	0.00477	CcSEcCtD
Frovatriptan—HTR1A—Monoamine GPCRs—DRD2—nicotine dependence	0.00399	0.0359	CbGpPWpGaD
Frovatriptan—Hypersensitivity—Varenicline—nicotine dependence	0.00385	0.00444	CcSEcCtD
Frovatriptan—Asthenia—Varenicline—nicotine dependence	0.00375	0.00433	CcSEcCtD
Frovatriptan—Pruritus—Varenicline—nicotine dependence	0.0037	0.00427	CcSEcCtD
Frovatriptan—HTR1D—G alpha (i) signalling events—TAS2R16—nicotine dependence	0.00365	0.0329	CbGpPWpGaD
Frovatriptan—HTR1B—cardiovascular system—nicotine dependence	0.00362	0.159	CbGeAlD
Frovatriptan—Diarrhoea—Varenicline—nicotine dependence	0.00357	0.00413	CcSEcCtD
Frovatriptan—HTR1B—G alpha (i) signalling events—TAS2R16—nicotine dependence	0.00357	0.0322	CbGpPWpGaD
Frovatriptan—HTR1D—cardiovascular system—nicotine dependence	0.00351	0.154	CbGeAlD
Frovatriptan—Dizziness—Varenicline—nicotine dependence	0.00346	0.00399	CcSEcCtD
Frovatriptan—HTR1A—Amine ligand-binding receptors—DRD2—nicotine dependence	0.00335	0.0302	CbGpPWpGaD
Frovatriptan—Vomiting—Varenicline—nicotine dependence	0.00332	0.00384	CcSEcCtD
Frovatriptan—Headache—Varenicline—nicotine dependence	0.00327	0.00378	CcSEcCtD
Frovatriptan—Nausea—Varenicline—nicotine dependence	0.0031	0.00358	CcSEcCtD
Frovatriptan—HTR1A—cardiovascular system—nicotine dependence	0.00292	0.128	CbGeAlD
Frovatriptan—HTR1B—midbrain—nicotine dependence	0.00283	0.124	CbGeAlD
Frovatriptan—HTR1D—midbrain—nicotine dependence	0.00274	0.12	CbGeAlD
Frovatriptan—HTR1A—G alpha (i) signalling events—TAS2R16—nicotine dependence	0.00272	0.0245	CbGpPWpGaD
Frovatriptan—HTR1A—SIDS Susceptibility Pathways—CHRNB4—nicotine dependence	0.00233	0.021	CbGpPWpGaD
Frovatriptan—HTR1A—midbrain—nicotine dependence	0.00228	0.1	CbGeAlD
Frovatriptan—CYP1A2—Cytochrome P450 - arranged by substrate type—CYP2A7—nicotine dependence	0.00227	0.0204	CbGpPWpGaD
Frovatriptan—CYP1A2—Oxidation by Cytochrome P450—CYP2A7—nicotine dependence	0.00224	0.0202	CbGpPWpGaD
Frovatriptan—HTR1D—GPCR ligand binding—TAS2R16—nicotine dependence	0.00221	0.0199	CbGpPWpGaD
Frovatriptan—HTR1B—GPCR ligand binding—TAS2R16—nicotine dependence	0.00216	0.0195	CbGpPWpGaD
Frovatriptan—CYP1A2—Phase 1 - Functionalization of compounds—CYP2A7—nicotine dependence	0.00184	0.0166	CbGpPWpGaD
Frovatriptan—HTR1B—brain—nicotine dependence	0.00178	0.0778	CbGeAlD
Frovatriptan—HTR1D—brain—nicotine dependence	0.00172	0.0754	CbGeAlD
Frovatriptan—HTR1A—GPCR ligand binding—TAS2R16—nicotine dependence	0.00165	0.0148	CbGpPWpGaD
Frovatriptan—HTR1A—SIDS Susceptibility Pathways—CHRNB2—nicotine dependence	0.00156	0.014	CbGpPWpGaD
Frovatriptan—HTR1D—G alpha (i) signalling events—OPRM1—nicotine dependence	0.00154	0.0139	CbGpPWpGaD
Frovatriptan—HTR1B—G alpha (i) signalling events—OPRM1—nicotine dependence	0.00151	0.0136	CbGpPWpGaD
Frovatriptan—HTR1A—brain—nicotine dependence	0.00144	0.0628	CbGeAlD
Frovatriptan—HTR1D—GPCRs, Class A Rhodopsin-like—OPRM1—nicotine dependence	0.00143	0.0129	CbGpPWpGaD
Frovatriptan—HTR1A—SIDS Susceptibility Pathways—CHRNA4—nicotine dependence	0.00141	0.0127	CbGpPWpGaD
Frovatriptan—HTR1B—GPCRs, Class A Rhodopsin-like—OPRM1—nicotine dependence	0.0014	0.0126	CbGpPWpGaD
Frovatriptan—HTR1D—GPCR downstream signaling—TAS2R16—nicotine dependence	0.00125	0.0112	CbGpPWpGaD
Frovatriptan—HTR1D—Class A/1 (Rhodopsin-like receptors)—OPRM1—nicotine dependence	0.00122	0.011	CbGpPWpGaD
Frovatriptan—HTR1B—GPCR downstream signaling—TAS2R16—nicotine dependence	0.00122	0.011	CbGpPWpGaD
Frovatriptan—HTR1B—Class A/1 (Rhodopsin-like receptors)—OPRM1—nicotine dependence	0.0012	0.0108	CbGpPWpGaD
Frovatriptan—HTR1A—G alpha (i) signalling events—OPRM1—nicotine dependence	0.00115	0.0103	CbGpPWpGaD
Frovatriptan—HTR1D—Signaling by GPCR—TAS2R16—nicotine dependence	0.00113	0.0102	CbGpPWpGaD
Frovatriptan—HTR1D—G alpha (i) signalling events—DRD2—nicotine dependence	0.00111	0.01	CbGpPWpGaD
Frovatriptan—HTR1B—Signaling by GPCR—TAS2R16—nicotine dependence	0.00111	0.01	CbGpPWpGaD
Frovatriptan—HTR1B—G alpha (i) signalling events—DRD2—nicotine dependence	0.00109	0.00981	CbGpPWpGaD
Frovatriptan—HTR1A—GPCRs, Class A Rhodopsin-like—OPRM1—nicotine dependence	0.00107	0.00959	CbGpPWpGaD
Frovatriptan—CYP1A2—Metapathway biotransformation—AKR1B10—nicotine dependence	0.00104	0.00934	CbGpPWpGaD
Frovatriptan—HTR1D—GPCRs, Class A Rhodopsin-like—DRD2—nicotine dependence	0.00103	0.0093	CbGpPWpGaD
Frovatriptan—HTR1B—GPCRs, Class A Rhodopsin-like—DRD2—nicotine dependence	0.00101	0.0091	CbGpPWpGaD
Frovatriptan—HTR1D—GPCR downstream signaling—FGD1—nicotine dependence	0.00098	0.00883	CbGpPWpGaD
Frovatriptan—CYP1A2—Biological oxidations—CYP2A7—nicotine dependence	0.000977	0.0088	CbGpPWpGaD
Frovatriptan—CYP1A2—Metapathway biotransformation—CYP2A7—nicotine dependence	0.000964	0.00868	CbGpPWpGaD
Frovatriptan—HTR1B—GPCR downstream signaling—FGD1—nicotine dependence	0.00096	0.00864	CbGpPWpGaD
Frovatriptan—HTR1D—GPCR ligand binding—OPRM1—nicotine dependence	0.000932	0.00839	CbGpPWpGaD
Frovatriptan—HTR1A—GPCR downstream signaling—TAS2R16—nicotine dependence	0.000932	0.00839	CbGpPWpGaD
Frovatriptan—HTR1A—Class A/1 (Rhodopsin-like receptors)—OPRM1—nicotine dependence	0.000913	0.00822	CbGpPWpGaD
Frovatriptan—HTR1B—GPCR ligand binding—OPRM1—nicotine dependence	0.000912	0.00822	CbGpPWpGaD
Frovatriptan—HTR1D—Signaling by GPCR—FGD1—nicotine dependence	0.00089	0.00802	CbGpPWpGaD
Frovatriptan—HTR1D—Class A/1 (Rhodopsin-like receptors)—DRD2—nicotine dependence	0.000885	0.00797	CbGpPWpGaD
Frovatriptan—HTR1B—Signaling by GPCR—FGD1—nicotine dependence	0.000871	0.00785	CbGpPWpGaD
Frovatriptan—HTR1B—Class A/1 (Rhodopsin-like receptors)—DRD2—nicotine dependence	0.000866	0.0078	CbGpPWpGaD
Frovatriptan—HTR1A—Signaling by GPCR—TAS2R16—nicotine dependence	0.000846	0.00762	CbGpPWpGaD
Frovatriptan—HTR1A—G alpha (i) signalling events—DRD2—nicotine dependence	0.00083	0.00747	CbGpPWpGaD
Frovatriptan—HTR1A—GPCRs, Class A Rhodopsin-like—DRD2—nicotine dependence	0.00077	0.00694	CbGpPWpGaD
Frovatriptan—HTR1A—GPCR downstream signaling—FGD1—nicotine dependence	0.000731	0.00658	CbGpPWpGaD
Frovatriptan—HTR1A—GPCR ligand binding—OPRM1—nicotine dependence	0.000695	0.00626	CbGpPWpGaD
Frovatriptan—HTR1D—GPCR ligand binding—DRD2—nicotine dependence	0.000674	0.00607	CbGpPWpGaD
Frovatriptan—HTR1D—Signaling Pathways—TAS2R16—nicotine dependence	0.00067	0.00603	CbGpPWpGaD
Frovatriptan—HTR1A—Signaling by GPCR—FGD1—nicotine dependence	0.000664	0.00598	CbGpPWpGaD
Frovatriptan—HTR1A—Class A/1 (Rhodopsin-like receptors)—DRD2—nicotine dependence	0.00066	0.00594	CbGpPWpGaD
Frovatriptan—HTR1B—GPCR ligand binding—DRD2—nicotine dependence	0.00066	0.00594	CbGpPWpGaD
Frovatriptan—HTR1B—Signaling Pathways—TAS2R16—nicotine dependence	0.000656	0.00591	CbGpPWpGaD
Frovatriptan—HTR1D—GPCR downstream signaling—OPRM1—nicotine dependence	0.000527	0.00474	CbGpPWpGaD
Frovatriptan—HTR1D—Signaling Pathways—FGD1—nicotine dependence	0.000526	0.00474	CbGpPWpGaD
Frovatriptan—HTR1B—GPCR downstream signaling—OPRM1—nicotine dependence	0.000516	0.00464	CbGpPWpGaD
Frovatriptan—HTR1B—Signaling Pathways—FGD1—nicotine dependence	0.000515	0.00464	CbGpPWpGaD
Frovatriptan—HTR1A—GPCR ligand binding—DRD2—nicotine dependence	0.000502	0.00453	CbGpPWpGaD
Frovatriptan—HTR1A—Signaling Pathways—TAS2R16—nicotine dependence	0.0005	0.0045	CbGpPWpGaD
Frovatriptan—HTR1D—Signaling by GPCR—OPRM1—nicotine dependence	0.000478	0.00431	CbGpPWpGaD
Frovatriptan—HTR1B—Signaling by GPCR—OPRM1—nicotine dependence	0.000468	0.00422	CbGpPWpGaD
Frovatriptan—HTR1D—Signaling Pathways—AKR1B10—nicotine dependence	0.000464	0.00418	CbGpPWpGaD
Frovatriptan—HTR1B—Signaling Pathways—AKR1B10—nicotine dependence	0.000455	0.0041	CbGpPWpGaD
Frovatriptan—HTR1A—GPCR downstream signaling—OPRM1—nicotine dependence	0.000393	0.00354	CbGpPWpGaD
Frovatriptan—HTR1A—Signaling Pathways—FGD1—nicotine dependence	0.000392	0.00353	CbGpPWpGaD
Frovatriptan—HTR1D—GPCR downstream signaling—DRD2—nicotine dependence	0.000381	0.00343	CbGpPWpGaD
Frovatriptan—HTR1B—GPCR downstream signaling—DRD2—nicotine dependence	0.000373	0.00336	CbGpPWpGaD
Frovatriptan—HTR1A—Signaling by GPCR—OPRM1—nicotine dependence	0.000357	0.00321	CbGpPWpGaD
Frovatriptan—HTR1A—Signaling Pathways—AKR1B10—nicotine dependence	0.000346	0.00312	CbGpPWpGaD
Frovatriptan—HTR1D—Signaling by GPCR—DRD2—nicotine dependence	0.000346	0.00311	CbGpPWpGaD
Frovatriptan—HTR1B—Signaling by GPCR—DRD2—nicotine dependence	0.000338	0.00305	CbGpPWpGaD
Frovatriptan—HTR1D—Signaling Pathways—WASF2—nicotine dependence	0.000327	0.00295	CbGpPWpGaD
Frovatriptan—HTR1B—Signaling Pathways—WASF2—nicotine dependence	0.00032	0.00289	CbGpPWpGaD
Frovatriptan—HTR1D—Signaling Pathways—WASF1—nicotine dependence	0.000314	0.00283	CbGpPWpGaD
Frovatriptan—HTR1B—Signaling Pathways—WASF1—nicotine dependence	0.000307	0.00277	CbGpPWpGaD
Frovatriptan—HTR1A—GPCR downstream signaling—DRD2—nicotine dependence	0.000284	0.00256	CbGpPWpGaD
Frovatriptan—HTR1D—Signaling Pathways—OPRM1—nicotine dependence	0.000282	0.00254	CbGpPWpGaD
Frovatriptan—HTR1B—Signaling Pathways—OPRM1—nicotine dependence	0.000277	0.00249	CbGpPWpGaD
Frovatriptan—HTR1A—Signaling by GPCR—DRD2—nicotine dependence	0.000258	0.00232	CbGpPWpGaD
Frovatriptan—HTR1A—Signaling Pathways—WASF2—nicotine dependence	0.000244	0.0022	CbGpPWpGaD
Frovatriptan—HTR1A—Signaling Pathways—WASF1—nicotine dependence	0.000234	0.00211	CbGpPWpGaD
Frovatriptan—HTR1A—Signaling Pathways—OPRM1—nicotine dependence	0.000211	0.0019	CbGpPWpGaD
Frovatriptan—HTR1D—Signaling Pathways—DRD2—nicotine dependence	0.000204	0.00184	CbGpPWpGaD
Frovatriptan—HTR1B—Signaling Pathways—DRD2—nicotine dependence	0.0002	0.0018	CbGpPWpGaD
Frovatriptan—CYP1A2—Metabolism—CYP2A7—nicotine dependence	0.000167	0.0015	CbGpPWpGaD
Frovatriptan—HTR1A—Signaling Pathways—DRD2—nicotine dependence	0.000152	0.00137	CbGpPWpGaD
